Axel Dalhoff

This inventor holds 4 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 2 EPO patents. Top assignees: Bayer Aktiengesellschaft, Morphochem Aktiengesellschaft Fur Kombinatorische Chemie, Morphochem Aktiengesellschaft Für Kombinatorishe Chemie. Active years: 2001-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Axel Dalhoff. Retrieved from https://idiyas.com/inventor/axel-dalhoff

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)

Company Filing History:

1 out of 12,268

Bayer Aktiengesellschaft

patents

1 out of 8

Morphochem Aktiengesellschaft Fur Kombinatorische Chemie

patents

1 out of 1

Morphochem Aktiengesellschaft Für Kombinatorishe Chemie

Years Active: 2001-2022

Loading Chart...

4 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11261205 - Oxazolidinone-quinolone hybrid antibacterial for the parenteral treatment of prophylaxis of bacterial diseases (2022-03-01),

2. 10723746 - Oxazolidinone-quinolone hybrid antibacterials for the parenteral treatment or prophylaxis of bacterial diseases (2020-07-28),

3. 9993469 - Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections (2018-06-12),

4. 6310216 - Special 3-azabicyclo[3.1.0]hexanes, method for producing and modifying the same, and their use (2001-10-30),

Title: The Innovations of Axel Dalhoff

Introduction

Axel Dalhoff is a notable inventor based in Wuppertal, Germany. He has made significant contributions to the field of antibacterial treatments, holding a total of four patents. His work focuses on the development of innovative hybrid compounds that aim to combat bacterial diseases effectively.

Latest Patents

Dalhoff's latest patents include the invention of oxazolidinone-quinolone hybrid antibacterials for the parenteral treatment and prophylaxis of bacterial diseases. These inventions relate to the use of oxazolidinone-quinolone hybrids, particularly for intravenous administration. The patents also encompass improved methods for administering these hybrid antibacterials, showcasing Dalhoff's commitment to enhancing treatment options for bacterial infections.

Career Highlights

Throughout his career, Dalhoff has worked with prominent companies in the pharmaceutical and chemical industries. Notably, he has been associated with Morphochem Aktiengesellschaft für Kombinatorische Chemie and Morphochem GmbH. His experience in these organizations has allowed him to develop and refine his innovative ideas in antibacterial treatments.

Collaborations

Dalhoff has collaborated with several professionals in his field, including Thomas Kapsner and Thomas Gramatte. These collaborations have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Axel Dalhoff's work in the field of antibacterial treatments exemplifies the importance of innovation in healthcare. His patents and collaborations reflect a dedication to improving medical solutions for bacterial diseases.

Profile summary based on public USPTO records.